Vircell has announced the launch of a new independent molecular control, Amplirun® Monkeypox Virus DNA Control, which will help laboratories all over the world to combat the current outbreak.
Despite the fact that the first human cases of monkeypox were reported in 1970 in several African countries, it has not been until May 2022 that multiple cases of monkeypox were identified in different non-endemic countries, causing the current outbreak.
By the time the World Health Organization (WHO) declared Moneypox a public health emergency of international concern in July 2022, Vircell had already developed several solutions in order to help laboratories to detect this new menace.
Among these solutions, Amplirun Monkeypox Virus DNA Control stands out as a positive amplification control that contains purified DNA of the Monkeypox virus, to be used as a control research technique based on nucleic acids amplification. Some great product features to note:
Amplirun Monkeypox Virus DNA Control could be used as:
Vircell is a leading provider of independent external run controls for nucleic acid testing with a long-term career in infectious disease diagnostics. During the COVID-19 pandemic, the company developed SARS-CoV-2 detection kits in record time, and now it is again demonstrating its ability to adapt to changing laboratory needs with their newest solutions.
Vircell is present at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, held in Chicago between the 24-28th of July, introducing this and other cutting-edge solutions in molecular biology such as their Real-Time PCR kit for Bacterial Meningitis. AACC is one of the leading events of the year to bring together the top professionals in the industry and an excellent opportunity to find leading solutions to combat the monkeypox outbreak.